Eli Lilly & Co.: PharmaVitae Profile

Publication Date	August 2008
Publisher	Datamonitor
Product Type	Report
Pages	117
ISBN Number	not applicable
Product Code	DAT13067

Price

£3,010.00
approximately: $4,398 | €3,299

PDF

PRINT £3,045 ($4,449 | €3,337)

Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for Eli Lilly in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Eli Lilly's performance against key rivals in the prescription pharmaceutical sector
Assess the commercial outlook for key new launch products Effiant and Byetta LAR
Evaluate Eli Lilly's ability to overcome the adverse impact of patent expiry for Zyprexa and other key franchises over the period 2011-13

Content

CHAPTER 1 ABOUT THIS PROFILE
- Executive summary
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
- Data sourcing
- Sales data
- Analyst consensus
CHAPTER 2 EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales performance, 200113
- Financial performance, 200113
- Eli Lilly: PharmaVitae forecasts at a glance
- Strategic insight
- Looking to partnerships for growth
- Outlook heavily dependent upon Effiant and Byetta LAR
- SWOT analysis
CHAPTER 3 QUARTERLY NEWS UPDATE
- Product developments
- Deals and alliances
- Product deals
- Technology deals
- M&A activity
- Company announcements
- Future product milestones
CHAPTER 4 COMPANY INTRODUCTION
- Key findings
- Background
- Key corporate developments
- M&A history
- Advanced Cardiovascular Systems (ACS) acquired
- Hybritech acquired
- DowElanco formed
- Devices for Vascular Intervention acquired
- Origin Medsystems
- Guidant spun-out
- Remaining medical device businesses divested
- PCS Health Systems acquired
- Hybritech divested
- DowElanco holding sold
- PCS Health Systems
- Applied Molecular Evolution
- ICOS acquired
- Ivy Animal Health acquired
- Hypnion acquired
- SGX Pharmaceuticals acquired
- M&A strategy
- Current corporate structure
- Pharmaceuticals
- Elanco Animal Health
CHAPTER 5 COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 200113
- Product analysis
- Product analysis, 200107
- Product analysis, 200713
- Therapy area analysis
- Therapy area analysis, 200107
- Therapy area analysis, 200713
- Therapy area focus, 200113
- Geographic analysis
- Geographic analysis, 200107
- Geographic analysis, 200713
- Geographic focus, 200113
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 200713
- Expiry analysis, 200713
- Launch/core/expiry configuration, 200713
- Molecule type analysis
- Molecule type analysis, 200107
- Molecule type analysis, 200713
- Externalization analysis
- Externalization analysis, 200107
- Externalization analysis, 200713
CHAPTER 6 COMPANY FINANCIALS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 200107
- Financial statements, 200107
- Profit and loss account, 200107
- Balance sheet, 200107
- Operating costs and profit analysis
- Operating costs and profit analysis, 200107
- Operating cost ratio and profit margin analysis, 200107
- Operating cost ratio and profit margin analysis, 200713
- Operating costs and profit analysis, 200713
- Return on capital employed analysis
- Capital employed analysis, 200107
- Return on capital employed (RoCE) analysis, 200107
- Market capitalization analysis
- Market capitalization analysis, 200107
- Total shareholder returns analysis, 200107
CHAPTER 7 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Central nervous system
- Cymbalta
- Zyprexa
- Endocrine, metabolic & genetic disorders
- Byetta franchise
- Oncology
- Alimta
- Gemzar
- Cardiovascular
- Effiant
CHAPTER 8 APPENDIX
- R&D pipeline
- References
- Abbreviations
- Exchange rates
TABLE OF TABLES
- Table 1: Eli Lilly PharmaVitae forecasts at a glance
- Table 2: Eli Lilly key product developments, Q1Q2 2008
- Table 3: Eli Lilly product deals and alliances, Q1Q2 2008
- Table 4: Eli Lilly technology deals and alliances, Q1Q2 2008
- Table 5: Eli Lilly M&A activity, Q1Q2 2008
- Table 6: Eli Lilly company announcements, Q1Q2 2008
- Table 7: Eli Lilly future product milestones, 200810
- Table 8: Eli Lilly product portfolio overview ($m), 200107
- Table 9: Eli Lilly product portfolio overview ($m), 200713
- Table 10: Eli Lilly product portfolio overview ($m), 200107
- Table 11: Eli Lilly product portfolio overview ($m), 200713
- Table 12: Eli Lilly portfolio overview by geographic region ($m), 200107
- Table 13: Eli Lilly portfolio overview by geographic region ($m), 200713
- Table 14: Eli Lilly launch portfolio overview ($m), 200713
- Table 15: Eli Lilly core portfolio overview ($m), 200713
- Table 16: Eli Lilly expiry portfolio overview ($m), 200713
- Table 17: Eli Lilly portfolio overview by molecule type ($m), 200107
- Table 18: Eli Lilly product portfolio overview by molecule type ($m), 200713
- Table 19: Eli Lilly product portfolio overview by source ($m), 200107
- Table 20: Eli Lilly product portfolio overview by source ($m), 200713
- Table 21: Total Eli Lilly sales by business unit ($m), 200107
- Table 22: Eli Lilly profit and loss account ($m), 200107
- Table 23: Eli Lilly balance sheet ($m), 200107
- Table 24: Eli Lilly operating revenue/cost analysis ($m), 200107
- Table 25: Eli Lilly operating cost ratio analysis (% of total revenues), 200107
- Table 26: Eli Lilly operating cost ratio analysis (% of total revenues), 200713
- Table 27: Eli Lilly operating revenue/cost analysis ($m), 200713
- Table 28: Eli Lilly capital employed ($m), 200107
- Table 29: Eli Lilly EBIT return on capital employed ($m), 2001-07
- Table 30: Eli Lilly EBIT pre-tax return/Capital employed driver analysis (%), 200107
- Table 31: Eli Lilly market capitalization ($ billion), 200107
- Table 32: Eli Lilly total shareholder returns (annual %), 200107
- Table 33: Key products overview
- Table 34: Cymbalta: overview
- Table 35: Cymbalta: sales forecast ($m), 200713
- Table 36: Zyprexa: overview
- Table 37: Zyprexa: sales forecast ($m), 200713
- Table 40: Byetta: overview
- Table 41: Byetta: sales forecast ($m), 200713
- Table 41: Byetta LAR: sales forecast ($m), 200713
- Table 42: Alimta: overview
- Table 43: Alimta: sales forecast ($m), 200713
- Table 44: Gemzar: overview
- Table 45: Gemzar: sales forecast ($m), 200713
- Table 38: Effiant: overview
- Table 39: Effiant: sales forecast ($m), 200713
- Table 54: Eli Lillys R&D pipeline (Phase Iregistration)
- Table 55: Exchange rates, 2007
TABLE OF FIGURES
- Figure1: Eli Lilly prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
- Figure2: Eli Lillys financial performance ($m), 200113
- Figure3: Impact of Year XYZ expiries on Eli Lillys pharmaceutical sales
- Figure4: Eli Lillys dependence upon key pipeline products
- Figure5: Eli Lilly SWOT analysis
- Figure6: M&A/divestment history
- Figure7: Current corporate structure
- Figure8: Eli Lilly prescription pharmaceutical performance, sales ($m) and growth rate (%), 200113
- Figure9: Eli Lilly key sales growth driver & resistors ($m), 200107
- Figure10: Eli Lilly key sales growth drivers & resistors ($m), 200713
- Figure11: Eli Lilly prescription pharmaceutical sales by therapy area ($m), 200113
- Figure12: Eli Lilly prescription pharma sales by therapy area (% of total), 200113
- Figure13: Eli Lilly prescription pharmaceutical sales by geographic region ($m), 200113
- Figure14: Eli Lilly growth drivers and resistors by geographic region ($m), 200107
- Figure15: Eli Lilly drivers and resistors by geographic region ($m), 200713
- Figure16: Eli Lilly prescription pharmaceutical sales by geographic region (% of total), 200113
- Figure17: Eli Lilly launch/core/expiry configuration ($m), 200713
- Figure18: Eli Lilly prescription pharmaceutical sales by molecule type ($m), 200113
- Figure19: Eli Lilly growth drivers and resistors by molecule type ($m), 200713
- Figure20: Eli Lilly prescription pharmaceutical sales by source ($m), 200113
- Figure21: Eli Lilly growth drivers and resistors by source ($m), 200107
- Figure22: Eli Lilly growth drivers and resistors by source ($m), 200713
- Figure23: Eli Lilly operating revenue/cost analysis ($m), 200113
- Figure24: Eli Lilly operating cost ratio analysis (% of total revenues), 200113
- Figure25: Eli Lilly return on capital employed, EBIT margin and capital turnover, 200107
- Figure26: Return on capital employed formula
- Figure27: Eli Lilly market capitalization ($ billion), 200107
- Figure28: Eli Lilly total shareholder returns vs. S&P 500 ($m), 200107